Research compound comparison · research use
CJC-1295 vs Ipamorelin: two receptors, one blend.
CJC-1295 and Ipamorelin are the two most cross-searched growth-hormone-secretagogue peptides, so buyers compare them constantly — but they aren't rivals. CJC-1295 is a GHRH-receptor analog (supplied with or without the DAC modification, i.e. Modified GRF 1-29); Ipamorelin is a short, selective ghrelin-receptor pentapeptide. They act at two different receptors, which is exactly why research protocols pair them — and why Titan supplies them as a single blended vial. This page lays out what each is, the DAC-vs-no-DAC molecular-weight check on the CJC-1295 COA, why a blend certificate has to confirm both peptides, and what to verify before sourcing either.
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Class | GHRH-receptor analog peptide (growth-hormone-releasing-hormone pathway) | Selective ghrelin / GHS-receptor agonist research pentapeptide (GHRP class) |
| Receptor studied | Studied at the GHRH receptor — the pathway associated with the amplitude and duration of growth-hormone pulses in laboratory models | Studied at a different receptor (the ghrelin / growth-hormone-secretagogue receptor) — associated with initiating a pulse, selectively in research models |
| Why they're compared | They are searched as rivals, but in research they act at two different receptors — which is exactly why protocols study them together rather than choosing one over the other | Same — the “vs” is usually answered by “both,” as the canonical paired-secretagogue research model |
| The #1 identity check | “CJC-1295” names two molecules — with DAC (Drug Affinity Complex) and without DAC (Modified GRF 1-29). They carry different masses, so the COA mass — not the label — tells you which is in the vial | A single defined 5-residue sequence, so the COA mass should match one expected value with little ambiguity |
| Approximate size | A ~29-residue GHRH(1-29) analog, with or without the DAC modification that extends its research half-life | A short pentapeptide — five amino acids in one defined sequence |
| Why the blend COA is different | Titan supplies these as a single blended research vial, so the release sheet must confirm the identity of BOTH components, not one | Same — a single purity number for a two-peptide blend cannot prove the ratio or that each half is full-length |
| Titan format | Supplied in the CJC-1295 + Ipamorelin blended research vial, lyophilized for reconstitution, lot-matched documentation | Same blended research vial; HPLC purity target with identity confirmation by mass, lot-matched documentation |
Two receptors, not two rivals
The structural distinction researchers care about: CJC-1295 is a GHRH-receptor analog, while Ipamorelin is a selective ghrelin / GHS-receptor agonist. They are studied at two different receptors, which is precisely why research protocols pair them rather than choose between them — and why Titan supplies them as a single blended vial. The common “CJC-1295 vs Ipamorelin” question usually resolves to “the blend.” Titan handles both strictly as research compounds, never as substitutes for any approved medication.
View the blend→On CJC-1295, read DAC vs no-DAC first
The single biggest sourcing trap in this pair is that “CJC-1295” is a trade name used for two different molecules: one with DAC (Drug Affinity Complex) and one without it (Modified GRF 1-29). Those carry different masses, so the molecular weight on the release sheet — not the product label — is what tells you which one you actually received. Confirm the reported mass against the form the supplier claims to ship before trusting anything else on the page.
Blend COA red flags→A blend means the COA must prove both
Verifying a single-peptide vial is one mass check; a two-peptide blend is not. The release sheet has to confirm each component's identity by mass and resolve the purity of both — a single blended purity number quietly hides which half is short or under-represented. That paper-trail standard — a lot-matched in-house release sheet referenced to the lot code on the unit, against an HPLC purity target with identity confirmation — is what separates a documented supplier from a blind one, and it is the only claim Titan makes about these compounds.
How to verify a COA→Choose by the receptor your model needs
Pick by what your research model is built around: GHRH-receptor work points to CJC-1295 — and there, confirm DAC vs no-DAC; ghrelin / GHS-receptor work points to Ipamorelin; the paired-secretagogue model points to the blend. Avoid any supplier that attaches growth, muscle, anti-aging, dosing, or human-use claims to either; that marketing language is a compliance red flag, not science. For an oral-secretagogue contrast, see MK-677 vs Ipamorelin.
Compare MK-677 vs Ipamorelin→Related reading
Keep comparing before you commit.
See the product page.
Open the CJC-1295 + Ipamorelin research blend for the lot documentation, blend purity workflow, and crypto checkout, or browse the full research catalog.
Compare research compounds
Other peptide comparisons researchers run before sourcing.
Each Titan comparison breaks down the structural differences, research format, and documentation a buyer should confirm — lot-matched COA, HPLC purity target, and a clear research-use boundary. Pick the pair you're evaluating.
GLP-1 / metabolic research
Growth-hormone secretagogue research
Recovery & repair research
Neuropeptide & nasal-format research